IRIS PubliCatt

De Luca, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.108
EU - Europa 6.671
AS - Asia 2.441
SA - Sud America 34
AF - Africa 30
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 6
Totale 16.299
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.030
DE - Germania 1.785
CN - Cina 1.270
SE - Svezia 1.078
UA - Ucraina 889
PL - Polonia 665
FR - Francia 632
SG - Singapore 555
IT - Italia 511
IE - Irlanda 382
ID - Indonesia 238
FI - Finlandia 225
GB - Regno Unito 210
IN - India 169
RU - Federazione Russa 145
TR - Turchia 81
CA - Canada 52
BE - Belgio 37
HK - Hong Kong 35
NL - Olanda 30
BR - Brasile 27
JP - Giappone 26
IR - Iran 23
ES - Italia 12
MX - Messico 12
BZ - Belize 11
AT - Austria 9
KR - Corea 9
CM - Camerun 8
LT - Lituania 8
CH - Svizzera 7
EU - Europa 7
VN - Vietnam 7
AE - Emirati Arabi Uniti 6
BG - Bulgaria 6
CI - Costa d'Avorio 6
PH - Filippine 6
RO - Romania 6
DK - Danimarca 5
GR - Grecia 5
EE - Estonia 4
AU - Australia 3
CL - Cile 3
CZ - Repubblica Ceca 3
EG - Egitto 3
GE - Georgia 3
KE - Kenya 3
LU - Lussemburgo 3
NZ - Nuova Zelanda 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BY - Bielorussia 2
ET - Etiopia 2
HU - Ungheria 2
LA - Repubblica Popolare Democratica del Laos 2
MA - Marocco 2
UG - Uganda 2
ZA - Sudafrica 2
AD - Andorra 1
AM - Armenia 1
AR - Argentina 1
BN - Brunei Darussalam 1
CO - Colombia 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
HN - Honduras 1
HR - Croazia 1
IL - Israele 1
IM - Isola di Man 1
IS - Islanda 1
LK - Sri Lanka 1
MD - Moldavia 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
PA - Panama 1
PE - Perù 1
PK - Pakistan 1
PT - Portogallo 1
RS - Serbia 1
TJ - Tagikistan 1
TN - Tunisia 1
Totale 16.299
Salva come PNG Salva come JPEG
Città #
Chandler 1.369
Jacksonville 569
Kraków 520
Ashburn 464
San Mateo 406
Singapore 403
Dublin 379
New York 300
Dearborn 287
Nanjing 275
Jakarta 238
Wilmington 229
Ann Arbor 171
Houston 168
Beijing 161
Lawrence 161
Cattolica 151
Redmond 143
Warsaw 143
Boston 139
Hangzhou 137
Woodbridge 132
Nürnberg 106
Moscow 104
Seattle 104
Nanchang 102
Redwood City 91
Milan 90
Izmir 78
Princeton 75
Lancaster 73
Boardman 69
Mountain View 67
University Park 64
Shenyang 58
Fairfield 54
Kunming 48
Bremen 43
Hebei 43
Norwalk 43
Guangzhou 41
Changsha 40
Rome 37
Brussels 36
Munich 35
Fremont 34
Jiaxing 34
Marseille 34
Ottawa 30
Hong Kong 29
Falls Church 28
Jinan 28
Philadelphia 28
Tianjin 28
San Jose 27
Shanghai 27
Pune 26
Cambridge 25
Los Angeles 25
Verona 24
Zhengzhou 22
Hefei 21
Leawood 21
Helsinki 20
Chicago 19
Scottsdale 19
Simi Valley 19
Washington 17
Paris 16
Indiana 14
London 14
Augusta 13
Toronto 13
Amsterdam 12
Detroit 12
Edinburgh 12
Fuzhou 12
Belize City 11
Las Vegas 11
Buffalo 9
Andover 8
Changchun 8
San Francisco 8
Wenzhou 8
Albuquerque 7
Auburn Hills 7
Lanzhou 7
Phoenixville 7
Urbino 7
Abidjan 6
Falkenstein 6
Kish 6
Saarbrücken 6
Santa Clara 6
Sofia 6
Tappahannock 6
Tokyo 6
Bari 5
Busto Arsizio 5
Chongqing 5
Totale 9.310
Salva come PNG Salva come JPEG
Nome #
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR 321
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 257
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 226
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 213
Common genetic variation and the control of HIV-1 in humans. 211
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 177
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 176
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 160
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 152
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 141
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 140
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 139
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 138
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 131
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. 123
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 123
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 120
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 120
Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia 118
Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria 114
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 113
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 109
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 109
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 108
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto SCTsuccessfully treated with combination treatment. 107
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar year: a cohort study 107
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 107
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 106
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 106
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 105
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. 103
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 103
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study 103
Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120 102
Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy. 102
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1 101
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 100
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 100
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? 99
Routine use of PCR-reverse cross-blot hybridization assay for rapid identification of Mycobacterium species growing in liquid media 99
Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis 98
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 97
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop 96
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 96
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 95
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 95
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 93
Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. 92
Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania 92
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure 92
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 92
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 92
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 91
Phemphigus vulgaris in a human-immunodeficiency-virus-infected patient. 90
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 89
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 89
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 89
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons 87
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 87
Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study 86
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. 86
Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity? 86
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 86
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 86
Prevalence of transmitted HIV-1 drug resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors 84
Hyperbilirubinemia during atazanavir treatment in 2404 patients in the Italian atazanavir expanded access program and MASTER Cohorts 84
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 83
Long term follow-up of Nevirapine-treated patients in a single centre cohort 82
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 82
Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy 82
Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe 82
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 82
Key questions in antiretroviral therapy: Italian Consensus Workshop (2005). 81
Lipid-lowering effect of tenofovir in HIV-infected patients 80
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 80
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 79
Evolution and predictors of HIV type 1 drug resistance in patients failing combination antiretroviral therapy in Italy 79
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 79
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 79
The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies 78
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 78
An outbreak of HIV-1 subtype G among Italian injecting drug users 77
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 77
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 76
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 76
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases 75
Stochastic Modelling of Genotypic Drug-Resistance for Human Immunodeficiency Virus towards Long-Term Combination Therapy Optimisation 75
Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. 75
Italian consensus statement on management of HIV-infected individualswith advanced disease naive to antiretroviral therapy 75
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 74
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 74
Interpretation systems for genotypic drug resistance of HIV-1 73
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study 73
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 73
Insulin resistance and HCV virologic response to peg-interferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV co-infected patients 72
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study 72
Routine use of PCR-reverse cross-blot hybridization assay for rapid identification of Mycobacterium species growing in liquid media 72
Impairment of recent thymic emigrants in HCV infection. 71
A novel methodology for large-scale phylogeny partition 71
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 71
Totale 10.347
Salva come PNG Salva come JPEG
Categoria #
all - tutte 72.434
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.434
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020911 0 0 0 0 0 0 152 94 116 132 188 229
2020/20211.750 134 207 45 199 215 99 191 31 272 38 280 39
2021/20221.870 185 198 43 94 68 81 31 315 70 137 260 388
2022/20233.527 475 477 286 502 307 453 82 297 448 36 106 58
2023/20241.724 73 554 31 136 51 379 79 34 18 28 190 151
2024/2025948 83 101 269 76 277 131 11 0 0 0 0 0
Totale 16.488